MARKET

MRNA

MRNA

Moderna
NASDAQ
105.49
-1.52
-1.42%
Opening 13:04 04/12 EDT
OPEN
106.00
PREV CLOSE
107.01
HIGH
107.88
LOW
104.80
VOLUME
1.07M
TURNOVER
0
52 WEEK HIGH
163.24
52 WEEK LOW
62.55
MARKET CAP
40.39B
P/E (TTM)
-8.5488
1D
5D
1M
3M
1Y
5Y
Benjamin Graham Detailed Fundamental Analysis - MRNA
NASDAQ · 1h ago
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
NASDAQ · 4h ago
1 New Green Flag for Moderna and Merck Stock
Moderna is developing a personalized cancer vaccine for head and neck cancers in conjunction with Merck. In a phase 1 trial, two patients with the disease responded well to the vaccine. The vaccine could be approved for sale in a handful of years. Moderna is the company behind the Spikevax coronavirus vaccine.
The Motley Fool · 4h ago
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
NASDAQ · 19h ago
Moderna (NASDAQ:MRNA) Postpones Plans of Vaccine Plant in Kenya
TipRanks · 1d ago
Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans
COVID-19 vaccine maker Moderna pauses plans to build a manufacturing plant in Kenya. The company has not received any vaccine orders for Africa since 2022. Moderna says it has faced $1 billion in losses and write-downs. The move signals a shift away from investing in pandemic preparedness in Africa.
Benzinga · 1d ago
Moderna: Considering The Cancer Vaccine Angle
Moderna, Inc. Is developing a vaccine-based treatment for head and neck cancer. The company's personalized neoantigen vaccine, mRNA-4157, has shown promising results in clinical trials for melanoma. MRNA has a wide range of therapeutic vaccines in development for cancer.
Seeking Alpha · 1d ago
BUZZ Investing: Echoes Of 'Mission Accomplished' Amid Inflation Battle
U.S. Stock markets ended 2023 on a high note after the Federal Reserve held interest rates steady. The BUZZ NextGen AI US Sentiment Leaders Index returned 11.75% during the month of December. The index finished ahead of the S&P 500 on the year with returns of 54.95% and 26.29%. Current investor sentiment indicates potential for positive momentum within crypto industry.
Seeking Alpha · 1d ago
More
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.

Webull offers Moderna Inc stock information, including NASDAQ: MRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRNA stock methods without spending real money on the virtual paper trading platform.